Alucent Biomedical Inc. articles

As part of our ongoing Vascular Innovation Series in conjunction with The Way to My Heart, journalist Kym McNicholas interviewed Alucent Biomedical CEO, Dr. Myles Greenberg.

Treatment for vascular blockages is getting a much-needed innovation makeover. Alucent’s first area of focus is one the most debilitating vascular diseases –peripheral artery disease, plaque build-up in mainly the legs that narrows blood flow causing excruciating pain. Their hope is to ultimately make

Start-up Alucent Biomedical is using a light-activated molecule, delivered via a balloon catheter, to create a natural vascular scaffold in diseased peripheral vessels, with the aim of providing a long-lasting treatment option that maintains patency while leaving nothing behind in the vessel.

Alucent Biomedical Inc. is rethinking peripheral artery disease (PAD) treatment with a novel natural scaffolding technology based on a light-activated drug therapy delivered via a balloon cathete